10 research outputs found
Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis
OBJECTIVES: Most patients with anti-NMDA receptor (NMDAR) encephalitis have intrathecal synthesis of antibodies, which cause a decrease of cell surface and synaptic NMDAR. Antibodies are immunoglobulin G (IgG)1 and IgG3 subtypes and can potentially activate complement. We examined whether complement immunoreactivity and antibody-secreting cells (plasma cells/plasmablasts) are present in the brain of these patients.
METHODS: Cultured rat hippocampal neurons were used in an immunocytochemical assay to test whether patients' antibodies can fix complement. Using the same reagents (antibodies to C9neo, C(5b-9), C3), complement immunoreactivity was determined in the brain of 5 patients, the teratoma of 21 patients, and appropriate control tissues. A set of markers for B (CD20), T (CD3, CD4, CD8) and antibody-secreting cells (plasma cells/plasmablasts, CD138) were used to examine the brain inflammatory infiltrates.
RESULTS: Patients' antibodies were able to bind complement in vitro, but deposits of complement were not detected in patients' brain. Parallel experiments with teratomas showed that in contrast to the brain, the neural tissue of the tumors contained complement. Analysis of the inflammatory infiltrates in brain samples from autopsy or biopsy performed 3-4 weeks after symptom presentation demonstrated numerous antibody-secreting cells (CD138+) in perivascular, interstitial, and Virchow-Robin spaces, and B and T cells predominantly located in perivascular regions.
CONCLUSIONS: Complement-mediated mechanisms do not appear to play a substantial pathogenic role in anti-NMDAR encephalitis. In contrast, there are copious infiltrates of antibody-secreting cells (plasma cells/plasmablasts) in the CNS of these patients. The demonstration of these cells provides an explanation for the intrathecal synthesis of antibodies and has implications for treatment
Genetic Testing to Inform Epilepsy Treatment Management From an International Study of Clinical Practice
IMPORTANCE: It is currently unknown how often and in which ways a genetic diagnosis given to a patient with epilepsy is associated with clinical management and outcomes.
OBJECTIVE: To evaluate how genetic diagnoses in patients with epilepsy are associated with clinical management and outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cross-sectional study of patients referred for multigene panel testing between March 18, 2016, and August 3, 2020, with outcomes reported between May and November 2020. The study setting included a commercial genetic testing laboratory and multicenter clinical practices. Patients with epilepsy, regardless of sociodemographic features, who received a pathogenic/likely pathogenic (P/LP) variant were included in the study. Case report forms were completed by all health care professionals.
EXPOSURES: Genetic test results.
MAIN OUTCOMES AND MEASURES: Clinical management changes after a genetic diagnosis (ie, 1 P/LP variant in autosomal dominant and X-linked diseases; 2 P/LP variants in autosomal recessive diseases) and subsequent patient outcomes as reported by health care professionals on case report forms.
RESULTS: Among 418 patients, median (IQR) age at the time of testing was 4 (1-10) years, with an age range of 0 to 52 years, and 53.8% (n = 225) were female individuals. The mean (SD) time from a genetic test order to case report form completion was 595 (368) days (range, 27-1673 days). A genetic diagnosis was associated with changes in clinical management for 208 patients (49.8%) and usually (81.7% of the time) within 3 months of receiving the result. The most common clinical management changes were the addition of a new medication (78 [21.7%]), the initiation of medication (51 [14.2%]), the referral of a patient to a specialist (48 [13.4%]), vigilance for subclinical or extraneurological disease features (46 [12.8%]), and the cessation of a medication (42 [11.7%]). Among 167 patients with follow-up clinical information available (mean [SD] time, 584 [365] days), 125 (74.9%) reported positive outcomes, 108 (64.7%) reported reduction or elimination of seizures, 37 (22.2%) had decreases in the severity of other clinical signs, and 11 (6.6%) had reduced medication adverse effects. A few patients reported worsening of outcomes, including a decline in their condition (20 [12.0%]), increased seizure frequency (6 [3.6%]), and adverse medication effects (3 [1.8%]). No clinical management changes were reported for 178 patients (42.6%).
CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study suggest that genetic testing of individuals with epilepsy may be materially associated with clinical decision-making and improved patient outcomes
Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis
Add-Âon cannabidiol in patients with Dravet syndrome: Results of a long-Âterm open-Âlabel extension trial
Objective: Add-on cannabidiol (CBD) reduced seizures associated with Dravet
syndrome (DS) in two randomized, double-blind, placebo-controlled trials:
GWPCARE1 Part B (NCT02091375) and GWPCARE2 (NCT02224703). Patients
whocompletedGWPCARE1 PartA(NCT02091206)orPartB,orGWPCARE2,were
enrolled in a long-term open-label extension trial, GWPCARE5 (NCT02224573).
We present an interim analysis of the safety, efficacy, and patient-reported outcomes from GWPCARE5.
Methods: Patientsreceived a pharmaceutical formulation of highly purified CBD
in oral solution (100 mg/ml), titrated from 2.5 to 20 mg/kg/day over a 2-week period, added to their existing medications. Based on response and tolerance, CBD
could be reduced or increased to 30 mg/kg/day.
Results: Of the 330 patients who completed the original randomized trials, 315
(95%) enrolled in this open-label extension. Median treatment duration was
444 days (range = 18–1535), with a mean modal dose of 22 mg/kg/day; patients
received a median of three concomitant antiseizure medications. Adverse events
(AEs)occurredin97%patients(mild,23%;moderate,50%;severe,25%).Commonly
reported AEs were diarrhea (43%), pyrexia (39%), decreased appetite (31%), and
somnolence (28%). Twenty-eight (9%) patients discontinued due to AEs. Sixtynine (22%) patients had liver transaminase elevations >3 Ă— upper limit of normal;
84% were on concomitant valproic acid. In patients from GWPCARE1 Part B and
GWPCARE2, the median reduction from baseline in monthly seizure frequency
assessed in 12-week periods up to Week 156 was 45%–74% for convulsive seizures
and 49%–84% for total seizures. Across all visit windows, ≥83% patients/caregivers completing a Subject/Caregiver Global Impression of Change scale reported
improvement in overall condition.
Significance: We show that long-term CBD treatment had an acceptable safety
profile and led to sustained, clinically meaningful reductionsin seizure frequency
in patients with treatment-resistant DS